Briquilimab Market Summary

Key Factors Driving Briquilimab Growth

1. Promising clinical efficacy in chronic spontaneous urticaria

Jasper reported encouraging updated results in January 2026 from its Phase 1b/2a BEACON study. In a small group of six additional patients receiving an initial 240 mg dose followed by 180 mg every eight weeks, 67% achieved a complete response at week 12, with a mean 31-point reduction in the Urticaria Activity Score over seven days (UAS7). These findings suggest potential to control persistent hives and itching in patients whose symptoms remain inadequately controlled despite high-dose antihistamines. However, the small sample size means larger controlled trials are necessary to establish the treatment effect reliably.

2. Potential for durable disease control with less frequent dosing

Briquilimab is administered subcutaneously, and the company's open-label extension study is evaluating a regimen of 180 mg every eight weeks. Among 36 CSU participants in the January 2026 update, 58% achieved a complete response and 75% achieved either a complete response or well-controlled disease at week 12. If subsequent studies confirm sustained efficacy with this schedule, the relatively infrequent injections could be an important advantage for patients requiring long-term treatment.

3. Differentiated anti-KIT mechanism of action

Unlike therapies that primarily block downstream inflammatory mediators, briquilimab targets KIT and disrupts the survival signal needed by mast cells. This approach aims to reduce the underlying population of mast cells responsible for releasing histamine and other inflammatory mediators. If the clinical benefit is confirmed, this mechanism could differentiate briquilimab from existing CSU treatments, including antihistamines and biologics targeting IgE or interleukin pathways.

4. Expansion opportunity in chronic inducible urticaria

CIndU is triggered by specific stimuli such as cold, pressure or temperature changes, and patients may continue to experience symptoms despite standard therapy. In the company's January 2026 open-label extension update, 65% of 17 CIndU participants achieved a complete or partial response at week 16, eight weeks after their second dose. Positive confirmatory results could broaden briquilimab's commercial opportunity beyond CSU, although the reported sample remains small.

5. Potential application in asthma and other mast-cell-driven diseases

Jasper reported preliminary proof-of-concept results from its ETESIAN asthma study in March 2026. Following a single 180 mg dose, investigators observed reductions in airway hyperresponsiveness and suppression of the eosinophilic response at weeks six and 12. These findings support further investigation, but they do not establish efficacy in the broader asthma population. The company has also identified other potential mast-cell-driven indications, including atopic dermatitis and food allergies, although these represent exploratory opportunities rather than established commercial markets.

Briquilimab Recent Developments

In July 2026, Jasper Therapeutics completed an all-stock merger with Kira Pharmaceuticals. The consolidated pipeline combines Kira's complement-targeted therapies (like KP-104) with Jasper's mast-cell program.

“Briquilimab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Briquilimab for potential indication like Chronic urticaria, Allergic asthma, Anaphylaxis, Atopic dermatitis, Fabry’s disease, and Gaucher’s disease in the 7MM. A detailed picture of Briquilimab’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Briquilimab for potential indications. The Briquilimab market report provides insights about Briquilimab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Briquilimab performance, future market assessments inclusive of the Briquilimab market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Briquilimab sales forecasts, along with factors driving its market.

Briquilimab Drug Summary

Briquilimab is an investigational, humanized monoclonal antibody developed by Jasper Therapeutics for the treatment of mast cell-driven inflammatory diseases and as a conditioning agent for hematopoietic stem cell transplantation and gene therapy. The drug targets CD117 (c-Kit), a cell-surface receptor expressed on hematopoietic stem cells and mast cells, by blocking the binding of stem cell factor (SCF) to its receptor and inhibiting the signaling required for cell survival and maintenance. In mast cell-mediated disorders, this mechanism is designed to reduce mast cell numbers and activity, potentially alleviating symptoms associated with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and allergic asthma. In transplantation, briquilimab aims to selectively deplete hematopoietic stem cells from the bone marrow before transplantation, potentially enabling engraftment while reducing reliance on conventional chemotherapy-based conditioning regimens and their associated toxicities. The drug has been investigated in clinical studies involving patients with chronic urticaria, lower-risk myelodysplastic syndromes (MDS), sickle cell disease, Fanconi anemia and severe combined immunodeficiency (SCID). The report provides Briquilimab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Briquilimab Market Report

The report provides insights into:

• A comprehensive product overview including the Briquilimab MoA, description, dosage and administration, research and development activities in potential indication like Chronic urticaria, Allergic asthma, Anaphylaxis, Atopic dermatitis, Fabry’s disease, and Gaucher’s disease.
• Elaborated details on Briquilimab regulatory milestones and other development activities have been provided in Briquilimab market report.
• The report also highlights Briquilimab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Briquilimab market report also covers the patents information, generic entry and impact on cost cut.
• The Briquilimab market report contains current and forecasted Briquilimab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Briquilimab market report also features the SWOT analysis with analyst views for Briquilimab in potential indications.

Methodology

The Briquilimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Briquilimab Analytical Perspective by DelveInsight

• In-depth Briquilimab Market Assessment

This Briquilimab sales market forecast report provides a detailed market assessment of Briquilimab for potential indication like Chronic urticaria, Allergic asthma, Anaphylaxis, Atopic dermatitis, Fabry’s disease, and Gaucher’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Briquilimab sales data uptil 2034.

• Briquilimab Clinical Assessment

The Briquilimab market report provides the clinical trials information of Briquilimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Briquilimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Briquilimab Market Potential & Revenue Forecast

• Projected market size for the Briquilimab and its key indications
• Estimated Briquilimab sales potential (Briquilimab peak sales forecasts)
• Briquilimab Pricing strategies and reimbursement landscape

Briquilimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Briquilimab Market positioning compared to existing treatments
• Briquilimab Strengths & weaknesses relative to competitors

Briquilimab Regulatory & Commercial Milestones

• Briquilimab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Briquilimab Clinical Differentiation

• Briquilimab Efficacy & safety advantages over existing drugs
• Briquilimab Unique selling points

Briquilimab Market Report Highlights

• In the coming years, the Briquilimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Briquilimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Briquilimab’s dominance.
• Other emerging products for Chronic urticaria, Allergic asthma, Anaphylaxis, Atopic dermatitis, Fabry’s disease, and Gaucher’s disease are expected to give tough market competition to Briquilimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Briquilimab in potential indications.
• Analyse Briquilimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Briquilimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Briquilimab in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Briquilimab? How strong is Briquilimab’s clinical and commercial performance?
• What is Briquilimab’s clinical trial status in each individual indications such as Chronic urticaria, Allergic asthma, Anaphylaxis, Atopic dermatitis, Fabry’s disease, and Gaucher’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Briquilimab Manufacturers?
• What are the key designations that have been granted to Briquilimab for potential indications? How are they going to impact Briquilimab’s penetration in various geographies?
• What is the current and forecasted Briquilimab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Briquilimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Briquilimab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Briquilimab? What is the duration of therapy and what are the geographical variations in cost per patient?